Elanco Animal Health Incorporated Q4 2025 Earnings Call Summary

Moby Intelligence

Tue, February 24, 2026 astatine 11:32 AM CST 3 min read

• Achieved 9% integrated changeless currency gross maturation successful Q4, marking 10 consecutive quarters of underlying maturation led by U.S. workplace and favored wellness sectors.

• Innovation gross reached $892 cardinal successful 2025, outperforming expectations owed to the accelerated adoption of the 'Big Six' products, peculiarly Credelio Quattro and Zenrelia.

• Credelio Quattro has go the fastest blockbuster successful institution history, gaining important stock successful the $1.4 cardinal U.S. broad-spectrum parasiticide marketplace done its unsocial four-ingredient differentiation.

• Zenrelia is exceeding planetary expectations with double-digit marketplace stock successful cardinal regions similar Brazil and Japan, driven by superior efficacy recognized by veterinarians.

• U.S. Farm Animal maturation of 17% was propelled by marketplace enactment successful cattle with Experior and Pradalex, contempt historically tiny herd sizes.

• The 'no-regret' motorboat strategy, supported by expanded income teams and DTC investment, is successfully converting innovation into marketplace stock gains crossed each large categories.

• Operational ratio and beardown currency absorption improved the nett leverage ratio to 3.6x up of interior timelines, portion the caller Elanco Ascend inaugural is acceptable to thrust further efficiencies starting successful 2026.

• Raised 2026 innovation gross people to $1.15 billion, assuming continued planetary scaling of the 'Big Six' and a motorboat of Befrena successful Q2 2026.

• Guidance assumes 4% to 6% integrated gross growth, supported by the highest terms increases for U.S. vet clinics successful 5 years to bespeak portfolio value.

• Management expects to scope a nett leverage ratio of 3.1x to 3.3x by year-end 2026, with a way to sub-3.0x successful 2027 done disciplined indebtedness paydown.

• The Elanco Ascend productivity programme is targeted to present $25 cardinal successful savings successful 2026, focusing connected G&A and manufacturing efficiencies to grow margins.

• Strategic acquisition of AHV International is expected to adjacent successful Q2 2026, providing a humble additive publication to dairy portfolio enactment without impacting deleveraging goals.

• Gross margins successful the archetypal fractional of 2026 look headwinds from the flow-through of higher-cost inventory and persistent inflationary pressures.

• Befrena motorboat follows a phased attack emblematic for monoclonal antibodies arsenic manufacturing bioreactors astatine the Elwood, Kansas installation standard up.

• Current U.S. guidance for Zenrelia conservatively assumes the existing statement remains 'as is,' portion absorption pursues a statement update aligned with planetary standards.

• Macroeconomic sensitivity remains a factor, though absorption believes innovation and strategical pricing supply insulation against broader marketplace volatility.